Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Young Investigator Awards Session Thrombosis Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

ESC 365 is supported by

ESC 365 is supported by